This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2014 Jun;9(6):e40-2.

doi: 10.1097/JTO.0000000000000103.

A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib

Naoki Omachi¹, Shigeki Shimizu, Tomoya Kawaguchi, Kenji Tezuka, Masaki Kanazu, Akihiro Tamiya, Kazuhiro Asami, Kyoichi Okishio, Masanori Kitaichi, Shinji Atagi

Affiliations

Affiliation

¹ Departments of *Internal Medicine, †Laboratory Medicine and Pathology, and ‡Surgery, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan.

PMID: 24828670
DOI: 10.1097/JTO.0000000000000103

Free article

Case Reports

A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib

Naoki Omachi et al. J Thorac Oncol. 2014 Jun.

Free article

. 2014 Jun;9(6):e40-2.

doi: 10.1097/JTO.0000000000000103.

Authors

Naoki Omachi¹, Shigeki Shimizu, Tomoya Kawaguchi, Kenji Tezuka, Masaki Kanazu, Akihiro Tamiya, Kazuhiro Asami, Kyoichi Okishio, Masanori Kitaichi, Shinji Atagi

Affiliation

¹ Departments of *Internal Medicine, †Laboratory Medicine and Pathology, and ‡Surgery, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan.

PMID: 24828670
DOI: 10.1097/JTO.0000000000000103

No abstract available

PubMed Disclaimer

Similar articles

A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
Anai S, Takeshita M, Ando N, Ikematsu Y, Mishima S, Ishida K, Inoue K. Anai S, et al. J Thorac Oncol. 2016 Oct;11(10):e126-8. doi: 10.1016/j.jtho.2016.07.008. J Thorac Oncol. 2016. PMID: 27663401 No abstract available.
Therapeutic effects of an ALK inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion.
Suetsugu T, Masada Y, Kozono T, Morita K, Yonezawa H, Tabata K, Seki N, Mizuno K, Tanaka K, Inoue H. Suetsugu T, et al. Respir Investig. 2024 Nov;62(6):1157-1160. doi: 10.1016/j.resinv.2024.09.013. Epub 2024 Oct 11. Respir Investig. 2024. PMID: 39395329
Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.
Wang S, Wu X, Zhao J, Chen H, Zhang Z, Wang M, Xu C, Wang Y, Wang L, He Z, Wang Q. Wang S, et al. Clin Lung Cancer. 2021 May;22(3):e366-e370. doi: 10.1016/j.cllc.2020.05.026. Epub 2020 Jun 2. Clin Lung Cancer. 2021. PMID: 32651063 No abstract available.
Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH, Mok K, Leung LK, Mok TS. Loong HH, et al. Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314. Future Oncol. 2015. PMID: 25757678 Review.
[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
Zhang HJ, Zhang XT, Zhang L. Zhang HJ, et al. Zhonghua Bing Li Xue Za Zhi. 2012 Dec;41(12):862-4. doi: 10.3760/cma.j.issn.0529-5807.2012.12.020. Zhonghua Bing Li Xue Za Zhi. 2012. PMID: 23324244 Review. Chinese. No abstract available.

See all similar articles

Cited by

Risk factors and prognostic factors for pulmonary large cell neuroendocrine carcinoma with brain metastasis.
Chen X, Huang Y, Chen F, She H, Chen X. Chen X, et al. Cancer Med. 2023 Feb;12(4):4087-4099. doi: 10.1002/cam4.5267. Epub 2022 Sep 20. Cancer Med. 2023. PMID: 36125491 Free PMC article.
Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma.
Kang K, Li B, Wang S, Wang J, Liang X. Kang K, et al. Front Oncol. 2024 Oct 22;14:1449490. doi: 10.3389/fonc.2024.1449490. eCollection 2024. Front Oncol. 2024. PMID: 39502318 Free PMC article. Review.
Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
Wiedemann C, Kazdal D, Cvetkovic J, Kunz J, Fisch D, Kirchner M, Kriegsmann M, Sültmann H, Heussel CP, Bischoff H, Thomas M, Stenzinger A, Christopoulos P. Wiedemann C, et al. Cold Spring Harb Mol Case Stud. 2022 Oct 28;8(6):a006234. doi: 10.1101/mcs.a006234. Print 2022 Oct. Cold Spring Harb Mol Case Stud. 2022. PMID: 36207130 Free PMC article.
Pulmonary Combined Large Cell Neuroendocrine Carcinoma.
Li M, Yang L, Lu H. Li M, et al. Pathol Oncol Res. 2022 Nov 23;28:1610747. doi: 10.3389/pore.2022.1610747. eCollection 2022. Pathol Oncol Res. 2022. PMID: 36507119 Free PMC article. Review.
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges.
Andrini E, Marchese PV, De Biase D, Mosconi C, Siepe G, Panzuto F, Ardizzoni A, Campana D, Lamberti G. Andrini E, et al. J Clin Med. 2022 Mar 7;11(5):1461. doi: 10.3390/jcm11051461. J Clin Med. 2022. PMID: 35268551 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information